Bristol-Myers Squibb Company

NYSE: BMY
$58.71
-$0.17 (-0.3%)
Real Time Data Delayed 15 Min.

BMY Articles

The April 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The analysts at BofA Securities have made a big move by removing a high-profile company from the firm's well-respected US 1 list of stocks to buy. Some other picks look especially intriguing now.
Exelixis stock jumped early on Monday after the company, in conjunction with Bristol-Myers Squibb, announced positive late-stage results from its kidney cancer study.
For cautious investors looking to avoid FANG stocks and the like, here are five that make sense now. They are reasonably conservative, pay good and reliable dividends, and also have good upside...
The March 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Some investors are looking for conservative growth ideas, and big pharma may be the ticket. These four top stocks have been hit hard, and the companies have paid dependable dividends for years.
As the U.S. economy starts to shut down, cash is king. These 10 public corporations have a tremendous amount of cash on their balance sheets.
Monday's top analyst calls included AbbVie, AES, AT&T, Boeing, Carnival, CME, Coca-Cola, Comcast, Honeywell, Lululemon Athletica, Netflix, Shopify, Starbucks and Twitter.
With interest rates still at generational lows, investors looking for income from stocks may be in the best place in a while. High-yielding, safer blue chips are available at rock bottom prices.
The February 28 short interest data have been compared with the previous figures, and short interest in these top pharmaceutical stocks decreased.
These five companies pay dividends, have shares that are rated Buy, tend to do well when the federal funds rate is cut and make good sense for worried investors now.
The February 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
With billions of dollars flowing in, it has become impossible to ignore the ESG trend. These 15 top ESG stocks appear to be undervalued against the performance of the broader markets.
The January 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
24/7 Wall St. screened the Merrill Lynch health care research database looking for large pharmaceutical leaders that also pay solid and dependable dividends. These five make sense for growth and...